Effects of collagen peptide supplementation on cardiovascular markers: a systematic review and meta-analysis of randomised, placebo-controlled trials

• Published in: British journal of nutrition Vol. 129; no. 5; pp. 779 - 794
• Main Authors: Jalili, Zahra, Jalili, Faramarz, Moradi, Sajjad, Bagheri, Reza, Moosavian, Seyedeh Parisa, Naeini, Fatemeh, Mohammadi, Hamed, Mojtaba Ghoreishy, Seyed, Wong, Alexei, Travica, Nikolaj, Hojjati Kermani, Mohammad Ali, Jalili, Cyrus
• Format: Journal Article
• Language: English
• Published: Cambridge, UK Cambridge University Press 14.03.2023
• Subjects: Bias; Blood Pressure; Body fat; Body mass; Body mass index; Cardiovascular Diseases - prevention & control; Cholesterol; Clinical trials; Collagen; Collagen (type I); Diabetes; Dietary Supplements; Fasting; Fat-free body mass; Heterogeneity; High density lipoprotein; Human and Clinical Nutrition; Humans; Hypertension; Intervention; Low density lipoprotein; Meta-analysis; Peptides; Placebos; Randomized Controlled Trials as Topic; Sensitivity analysis; Supplements; Systematic review; Systematic Review and Meta-Analysis; Japan; Germany; Glycaemic markers; Cardiovascular; Health; Body composition
• ISSN: 0007-1145; 1475-2662
• DOI: 10.1017/S0007114522001301

Previous studies have advocated that collagen peptide supplementation (CPS) can positively affect cardiovascular health. However, the widespread impact of CPS on CVD-related markers is not fully resolved. Consequently, the current systematic review and meta-analysis aimed to assess the efficacy of CPS on CVD-related markers. A systematic search in the Scopus, PubMed and ISI Web of Science databases were completed to identify relevant randomised, placebo-controlled trials (RCT) published up to November 2021. Mean Differences were pooled using a random-effects model, while publication bias, sensitivity analyses and heterogeneity were assessed using previously validated methods. Twelve RCT, comprising of a total of eleven measured markers, were selected for the quantitative analysis. Pooled data revealed that CPS significantly decreased fat mass (–1·21 kg; 95 % CI: −2·13, −0·29; I2 = 0·0 %; P = 0·010) and increased fat-free mass, based on body mass percentage (1·49 %; 95 % CI: 0·57, 2·42; I2 = 0·0 %; P = 0·002). Moreover, collagen peptide supplementation led to a significant decrease in serum LDL (–4·09 mg/dl; 95 % CI: −8·13, −0·04; I2 = 93·4 %; P = 0·048) and systolic blood pressure (SBP) (–5·04 mmHg; 95 % CI: −9·22, −0·85; I2 = 98·9 %; P = 0·018). Our analysis also indicated that CPS did not affect glycemic markers. Our outcomes indicate that CPS reduces fat mass, LDL and SBP while increasing fat-free mass. Future investigations with longer CPS duration are needed to expand on our results.